title: Assessment of tumour response to chemotherapy for metastatic colorectal cancer: accuracy of the RECIST criteria.
abstract: Evaluation of tumour size modifications in response to treatment is a critical issue in the management of advanced malignancies. In 1981, the World Health Organization (WHO) established guidelines for tumour response assessment. These WHO1981 criteria were recently simplified in a revised version, named RECIST (Response Evaluation Criteria in Solid Tumours), which uses unidimensional instead of bidimensional measurements, a reduced number of measured lesions, withdrawal of the progression criteria based on isolated increase of a single lesion, and different shrinkage threshold for definitions of tumour response and progression. In order to validate these new guidelines, we have compared results obtained with both classifications in a prospective series of 91 patients receiving chemotherapy for metastatic colorectal cancer. Data from iterative tomographic measurements were fully recorded and reviewed by an expert panel. The overall response and progression rates according to the WHO1981 criteria were 19% and 58%, respectively. Using RECIST criteria, 16 patients were reclassified in a more favourable subgroup, the overall response rate being 28% and the progression rate 45% (non-weighted kappa concordance test 0.72). When isolated increase of a single measurable lesion is not taken into account for progression with the WHO1981 criteria, only 7 patients were reclassified and the kappa test was satisfying, i.e. > or =0.75, for the whole population as well as for each of the responding and progressive subgroups. Since it provides concordant results with a simplified method, the use of RECIST criteria is recommended for evaluation of treatment efficacy in clinical trials and routine practice.
authors.affiliation: Department of Medical Oncology, Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, 69495 Pierre Bénite, France.
authors.forename: V
authors.initials: V
authors.lastname: Trillet-Lenoir
authors.forename: G
authors.initials: G
authors.lastname: Freyer
authors.forename: P
authors.initials: P
authors.lastname: Kaemmerlen
authors.forename: A
authors.initials: A
authors.lastname: Fond
authors.forename: O
authors.initials: O
authors.lastname: Pellet
authors.forename: C
authors.initials: C
authors.lastname: Lombard-Bohas
authors.forename: J L
authors.initials: JL
authors.lastname: Gaudin
authors.forename: G
authors.initials: G
authors.lastname: Lledo
authors.forename: R
authors.initials: R
authors.lastname: Mackiewicz
authors.forename: M C
authors.initials: MC
authors.lastname: Gouttebel
authors.forename: H
authors.initials: H
authors.lastname: Moindrot
authors.forename: J D
authors.initials: JD
authors.lastname: Boyer
authors.forename: L
authors.initials: L
authors.lastname: Chassignol
authors.forename: N
authors.initials: N
authors.lastname: Stremsdoerfer
authors.forename: F
authors.initials: F
authors.lastname: Desseigne
authors.forename: J M
authors.initials: JM
authors.lastname: Moreau
authors.forename: F
authors.initials: F
authors.lastname: Hedelius
authors.forename: A
authors.initials: A
authors.lastname: Moraillon
authors.forename: F
authors.initials: F
authors.lastname: Chapuis
authors.forename: J P
authors.initials: JP
authors.lastname: Bleuse
authors.forename: Y
authors.initials: Y
authors.lastname: Barbier
authors.forename: M O
authors.initials: MO
authors.lastname: Heilmann
authors.forename: P J
authors.initials: PJ
authors.lastname: Valette
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000473:pathology / Q000556:secondary*; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D015179:Colorectal Neoplasms / Q000473:pathology*; D018450:Disease Progression; D005260:Female; D006305:Health Status Indicators; D006801:Humans; D008297:Male; D008875:Middle Aged; D017410:Practice Guidelines as Topic; D011446:Prospective Studies; D015996:Survival Rate; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents